Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 183

Sort by

Sort Order Select

Journal Articles

Real-world efficacy and safety of ixazomib maintenance therapy in Chinese patients with newly diagnosed multiple myeloma: A multicenter retrospective study

Junnan Li, Xin Wang, Shuangnian Xu, Dongfeng Zeng, Yi Yang

Blood (2025) 146 (Supplement 1): 7544.

https://doi.org/10.1182/blood-2025-7544

Published: 2025

Journal Articles

Transition to ixazomib-based maintenance following daratumumab-based induction for continuous therapy in newly diagnosed multiple myeloma

Junnan Li, Xin Wang, Shuangnian Xu, Dongfeng Zeng, Yi Yang

Blood (2025) 146 (Supplement 1): 7517.

https://doi.org/10.1182/blood-2025-7517

Published: 2025

Journal Articles

Chronic myelomonocytic leukemia: Clinical outcomes from clinical trials submitted to the FDA over the past 25 years

Yanxia Li, Radhika Avadhani, dianne pulte, Chatchada Karanes, Ilynn Bulatao, Nina Kim, Frank Cross, Xin Wang, Kelly Norsworthy

Blood (2025) 146 (Supplement 1): 2073.

https://doi.org/10.1182/blood-2025-2073

Published: 2025

Journal Articles

Initial phase 1b/2 study results with sonrotoclax (BGB-11417) in combination with carfilzomib and dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma

Hang Quach, Rakesh Popat, Wenming Chen, Mary Kwok, Andrew Yee, Zhongxing Jiang, Flávia Xavier, Natalie Callander, Man Yuk Ho, Susan Bal, Michael Low, Douglas Sborov, Gabriel Man, Huan Cheng, Adam Idoine, Xin Wang, Amit Agarwal, Binod Dhakal

Blood (2025) 146 (Supplement 1): 102.

https://doi.org/10.1182/blood-2025-102

Published: 2025

Journal Articles

A cyno cross reactive CD3 VHH antibody enables engineering of a potent CD20-targeted t cell engager with enhanced safety

Blood (2025) 146 (Supplement 1): 3297.

https://doi.org/10.1182/blood-2025-3297

Published: 2025

Journal Articles

Integrated machine learning-based prognostic models for patients with Myelodysplastic Syndromes/neoplasms (MDS)

Xin Wang, Qiujin Shen, Saibing Qi, Xiaowen Gong, Tiejun Qin, Zefeng Xu, Bing Li, Shiqiang Qu, Binhan Jiang, Yue Zhong, Lijuan Pan, Meng Jiao, Qingyan Gao, Robert Gale, Junren Chen, Zhijian Xiao

Blood (2025) 146 (Supplement 1): 7385.

https://doi.org/10.1182/blood-2025-7385

Published: 2025

Journal Articles

Unifying the classification of acute myeloid leukemia, myelodysplasia-related: A multi-institutional experience

Ying Liu, Derek Loneman, Brenden Bready, David Nemirovsky, Xin Wang, Eytan Stein, Andriy Derkach, Robert Hasserjian, Wenbin Xiao

Blood (2025) 146 (Supplement 1): 219.

https://doi.org/10.1182/blood-2025-219

Published: 2025

Journal Articles

Mass spectrometry-based screening for monoclonal gammopathy in individuals undergoing physical examinations: Analyses of consecutive 15,068 cases in China

Zi-han Yang, Li-xin Wang, Yu-xi Wang, Qian Di, Wei Su, Jian-hua Han, Jian Li

Blood (2025) 146 (Supplement 1): 5744.

https://doi.org/10.1182/blood-2025-5744

Published: 2025

Journal Articles

A phase 1 dose escalation and dose optimization study to evaluate the preliminary safety, tolerability, pharmacokinetic, pharmacodynamic, and clinical activity profile of AUTX703 in participants with relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes

Blood (2025) 146 (Supplement 1): 6952.

https://doi.org/10.1182/blood-2025-6952

Published: 2025

Journal Articles

The role of aging in promoting leukemia progression through cell-intrinsic and cell-extrinsic mechanisms

Blood (2025) 146 (Supplement 1): 6704.

https://doi.org/10.1182/blood-2025-6704

Published: 2025

Journal Articles

Rethinking disparity in Acute Myeloid Leukemia, a new perspective in the Asian population

Agomoni Saha, Andriy Derkach, Wenbin Xiao, Eytan Stein, Ying Liu, Xin Wang

Blood (2025) 146 (Supplement 1): 38.

https://doi.org/10.1182/blood-2025-38

Published: 2025

Journal Articles

Efficacy and safety of pola-based therapy in molecularly defined high-risk DLBCL: A retrospective analysis of real-world data

Xi Dou, Yiying Xiong, Lanxiang Liu, Xiaoqiong Tang, Hongbin Zhang, Xin Wang, Jianbin Chen, Lin Liu, Li Wang

Blood (2025) 146 (Supplement 1): 8083.

https://doi.org/10.1182/blood-2025-8083

Published: 2025

Journal Articles

primary efficacy and safety of first-line R-MTO regimen (rituximab, methotrexate, thiotepa, and orelabrutinib) followed by autologous hematopoietic stem cell transplantation in PCNSL

Haichen Wei, Xin Wang, Lijie Xing, Dan Liu, Hui Wang, Ping Li, Zengjun Li

Blood (2025) 146 (Supplement 1): 3687.

https://doi.org/10.1182/blood-2025-3687

Published: 2025

Journal Articles

A randomized Phase II trial of ASTX727 and venetoclax with or without enasidenib for newly diagnosed older adults with IDH2 mutant Acute Myeloid Leukemia: A myelomatch substudy (MM1OA-S03)

Eric Huselton, Uma Borate, John Reagan, Richard Little, Steven Gore, Megan Othus, Anna Moseley, Manu Pandey, Xin Wang, Laura Michaelis, Geoffrey Uy, Anjali Advani, Harry Erba

Blood (2025) 146 (Supplement 1): 3466.

https://doi.org/10.1182/blood-2025-3466

Published: 2025

Journal Articles

Factor XI haploinsufficiency is protective against venous thromboembolism and myocardial infarction in population-scale multidimensional datasets

Alfonso Rodriguez Espada, Amelia Haj, Sean Jurgens, Justine Ryu, Xin Wang, Seung Hoan Choi, Steven Grover, Patrick Ellinor, Pavan Bendapudi

Blood (2025) 146 (Supplement 1): 1281.

https://doi.org/10.1182/blood-2025-1281

Published: 2025

Journal Articles

Use of population-scale multiomics to define the prothrombotic phenotype of Protein C deficiency

Alfonso Rodriguez Espada, Amelia Haj, Sean Jurgens, Sharjeel Chaudhry, Justine Ryu, Xin Wang, Seung Hoan Choi, Patrick Ellinor, Steven Grover, Kenneth Bauer, Pavan Bendapudi

Blood (2025) 146 (Supplement 1): 1278.

https://doi.org/10.1182/blood-2025-1278

Published: 2025

Journal Articles

Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies

Blood (2024) 144 (23): 2375–2388.

https://doi.org/10.1182/blood.2023023616

Published: 2024

Includes: Supplemental data

Journal Articles

The Use of Antifungal Prophylaxis Is Associated with Worse Outcomes in Patients with Newly Diagnosed AML Treated with Venetoclax/HMA: A Retrospective Analysis of Patients in the Flatiron Health Database

Alexander J. Ambinder, Mark J. Levis, Xin Wang, Keith W. Pratz, Andrew H Matthews

Blood (2024) 144 (Supplement 1): 2436.

https://doi.org/10.1182/blood-2024-207062

Published: 2024

Journal Articles

Study of PC-002 (Sepantronium Bromide), a First-in-Class Inhibitor of Deubiquitinases (DUBs) Targeting Myc Degradation in Relapsed/Refractory c-Myc Rearranged High-Grade B Cell Lymphoma (HGBCL): Updated Phase 2 Results

Blood (2024) 144 (Supplement 1): 3120.

https://doi.org/10.1182/blood-2024-206700

Published: 2024

Journal Articles

Efficacy and Safety of Primary Letermovir Prophylaxis for Cytomegalovirus Infection in Pediatric Patients Undergoing Allogeneic Transplantation: A Single-Centre, Retrospective, Real-World Analysis

Xin Wang, Chaoqian Jiang, Lipeng Liu, Xia Chen, Yuanyuan Ren, Yang Wan, Aoli Zhang, Xiaoyan Zhang, Yue Shang, Yao Zou, Xiaojuan Chen, Fang Liu, Wenyu Yang, Xiaofan Zhu, Ye Guo

Blood (2024) 144 (Supplement 1): 7274.

https://doi.org/10.1182/blood-2024-197912

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Real-world efficacy and safety of ixazomib maintenance therapy in Chinese patients with newly diagnosed multiple myeloma: A multicenter retrospective study

Transition to ixazomib-based maintenance following daratumumab-based induction for continuous therapy in newly diagnosed multiple myeloma

Chronic myelomonocytic leukemia: Clinical outcomes from clinical trials submitted to the FDA over the past 25 years

Initial phase 1b/2 study results with sonrotoclax (BGB-11417) in combination with carfilzomib and dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma

A cyno cross reactive CD3 VHH antibody enables engineering of a potent CD20-targeted t cell engager with enhanced safety

Integrated machine learning-based prognostic models for patients with Myelodysplastic Syndromes/neoplasms (MDS)

Unifying the classification of acute myeloid leukemia, myelodysplasia-related: A multi-institutional experience

Mass spectrometry-based screening for monoclonal gammopathy in individuals undergoing physical examinations: Analyses of consecutive 15,068 cases in China

A phase 1 dose escalation and dose optimization study to evaluate the preliminary safety, tolerability, pharmacokinetic, pharmacodynamic, and clinical activity profile of AUTX703 in participants with relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes

The role of aging in promoting leukemia progression through cell-intrinsic and cell-extrinsic mechanisms

Rethinking disparity in Acute Myeloid Leukemia, a new perspective in the Asian population

Efficacy and safety of pola-based therapy in molecularly defined high-risk DLBCL: A retrospective analysis of real-world data

primary efficacy and safety of first-line R-MTO regimen (rituximab, methotrexate, thiotepa, and orelabrutinib) followed by autologous hematopoietic stem cell transplantation in PCNSL

A randomized Phase II trial of ASTX727 and venetoclax with or without enasidenib for newly diagnosed older adults with IDH2 mutant Acute Myeloid Leukemia: A myelomatch substudy (MM1OA-S03)

Factor XI haploinsufficiency is protective against venous thromboembolism and myocardial infarction in population-scale multidimensional datasets

Use of population-scale multiomics to define the prothrombotic phenotype of Protein C deficiency

Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies

The Use of Antifungal Prophylaxis Is Associated with Worse Outcomes in Patients with Newly Diagnosed AML Treated with Venetoclax/HMA: A Retrospective Analysis of Patients in the Flatiron Health Database

Study of PC-002 (Sepantronium Bromide), a First-in-Class Inhibitor of Deubiquitinases (DUBs) Targeting Myc Degradation in Relapsed/Refractory c-Myc Rearranged High-Grade B Cell Lymphoma (HGBCL): Updated Phase 2 Results

Efficacy and Safety of Primary Letermovir Prophylaxis for Cytomegalovirus Infection in Pediatric Patients Undergoing Allogeneic Transplantation: A Single-Centre, Retrospective, Real-World Analysis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only